{"id":"F2021L01912","name":"Statement of Principles concerning hyperthyroidism and thyrotoxicosis (Reasonable Hypothesis) (No. 5 of 2022)","slug":"statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441149,"registerId":"F2021L01912-fast-fetch-1775956527007","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning hyperthyroidism and thyrotoxicosis (Reasonable Hypothesis) (No. 5 of 2022)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 22.10.0\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nHYPERTHYROIDISM AND THYROTOXICOSIS (Reasonable Hypothesis)\n\n(No. 5 of 2022)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 24 December 2021\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning hyperthyroidism and thyrotoxicosis (Reasonable Hypothesis) (No. 5 of 2022).\n\n2 Commencement\n\n This instrument commences on 31 January 2022.\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning hyperthyroidism and thyrotoxicosis No. 27 of 2013 (Federal Register of Legislation No. F2013L00723) made under subsection 196B(2) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about hyperthyroidism and thyrotoxicosis and death from hyperthyroidism and thyrotoxicosis.\n\nMeaning of hyperthyroidism\n\n(2) For the purposes of this Statement of Principles, hyperthyroidism:\n\n(a) means a functional endocrine disorder in which the thyroid gland synthesises and secretes excessive amounts of thyroid hormone sufficient to produce clinical symptoms and signs of thyroid hyperfunction or to warrant medical treatment; and\n\n(b) excludes:\n\n(i) euthyroid hyperthyroxinaemia;\n\n(ii) gestational transient thyrotoxicosis;\n\n(iii) Graves disease;\n\n(iv) sick euthyroid syndrome; and\n\n(v) toxic multinodular goitre and toxic thyroid adenoma.\n\nNote 1: Hyperthyroidism typically presents with elevated serum concentrations of the thyroid hormones thyroxine (T4) and/or triiodothyronine (T3), and usually with a reduced concentration of thyroid-stimulating hormone.\n\nNote 2: Clinical symptoms and signs of thyroid hyperfunction are nonspecific and typically include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration and weight loss.\n\nNote 3: Hyperthyroidism due to toxic multinodular goitre or toxic thyroid adenoma is covered by the Statements of Principles concerning goitre. In the circumstance where hyperthyroidism is due to Graves disease, it is covered by the Statements of Principles concerning Graves disease.\n\nNote 4: Hyperthyroidism may be acute or chronic. The acute form may present as a thyrotoxic crisis.\n\nNote 5: thyrotoxic crisis is defined in the Schedule 1 - Dictionary.\n\nMeaning of thyrotoxicosis\n\n(3) For the purposes of this Statement of Principles, thyrotoxicosis:\n\n(a) means a functional endocrine disorder that results from the action of inappropriately high thyroid hormone levels in tissues sufficient to produce clinical symptoms and signs of thyroid hyperfunction or to warrant medical treatment; and\n\n(b) excludes:\n\n(i) euthyroid hyperthyroxinaemia;\n\n(ii) gestational transient thyrotoxicosis;\n\n(iii) Graves disease;\n\n(iv) sick euthyroid syndrome; and\n\n(v) toxic multinodular goitre and toxic thyroid adenoma.\n\nNote 1: Inappropriately high thyroid hormone levels in thyrotoxicosis can arise from endogenous or exogenous sources.\n\nNote 2: Thyrotoxicosis typically presents with elevated serum concentrations of the thyroid hormones thyroxine (T4) and/or triiodothyronine (T3), and usually with a reduced concentration of thyroid-stimulating hormone.\n\nNote 3: Clinical symptoms and signs of thyroid hyperfunction are nonspecific and typically include anxiety, emotional lability, weakness, tremor, palpitations, heat intolerance, increased perspiration and weight loss.\n\nNote 4: Thyrotoxicosis due to toxic multinodular goitre or toxic thyroid adenoma is covered by the Statements of Principles concerning goitre. In the circumstance where thyrotoxicosis is a clinical manifestation of Graves disease, it is covered by the Statements of Principles concerning Graves disease.\n\nNote 5: Thyrotoxicosis may be acute or chronic. The acute form may present as a thyrotoxic crisis.\n\nNote 6: thyrotoxic crisis is defined in the Schedule 1 - Dictionary.\n\nDeath from hyperthyroidism or thyrotoxicosis\n\n(4) For the purposes of this Statement of Principles, hyperthyroidism or thyrotoxicosis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's hyperthyroidism or thyrotoxicosis.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that hyperthyroidism or thyrotoxicosis and death from hyperthyroidism or thyrotoxicosis can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting hyperthyroidism or thyrotoxicosis or death from hyperthyroidism or thyrotoxicosis with the circumstances of a person's relevant service:\n\n(1) having iodine excess within the 6 months before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\nNote 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine.\n\nNote 2: iodine excess is defined in the Schedule 1 - Dictionary.\n\n(2) being administered an iodine-containing radiographic contrast agent within the 6 months before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(3) taking amiodarone for a continuous period of at least 2 weeks, within the 1 year before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(4) taking a drug from the specified list of drugs within the 6 months before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(5) taking minocycline for at least the 6 months before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(6) taking a drug containing at least 10 milligrams of iodine daily for a continuous period of at least 4 weeks, within the 6 months before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(7) having a thyroid-stimulating, hormone-secreting pituitary adenoma at the time of the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(8) having a chorionic gonadotrophin-secreting neoplasm at the time of the clinical onset of hyperthyroidism or thyrotoxicosis;\n\nNote: chorionic gonadotrophin-secreting neoplasm is defined in the Schedule 1 - Dictionary.\n\n(9) having a primary or metastatic neoplasm involving the thyroid gland at the time of the clinical onset of hyperthyroidism or thyrotoxicosis;\n\n(10) for hyperthyroidism or thyrotoxicosis first presenting as thyrotoxic crisis only, having an acute precipitating event within the 48 hours before the clinical onset of hyperthyroidism or thyrotoxicosis;\n\nNote: acute precipitating event and thyrotoxic crisis are defined in the Schedule 1 - Dictionary.\n\n(11) for thyrotoxicosis only:\n\n(a) having struma ovarii at the time of the clinical onset of thyrotoxicosis;\n\nNote: struma ovarii is defined in the Schedule 1 - Dictionary.\n\n(b) having metastatic thyroid carcinoma containing functional thyroid tissue at the time of the clinical onset of thyrotoxicosis;\n\n(c) having a form of thyroiditis from the specified list of forms of thyroiditis at the time of the clinical onset of thyrotoxicosis;\n\nNote: specified list of forms of thyroiditis is defined in the Schedule 1 - Dictionary.\n\n(d) having trauma involving the thyroid gland within the 14 days before the clinical onset of thyrotoxicosis;\n\nNote: trauma involving the thyroid gland is defined in the Schedule 1 - Dictionary.\n\n(e) ingesting excess thyroid hormone in medication, dietary supplements or in food containing thyroid extracts within the 3 months before the clinical onset of thyrotoxicosis;\n\n(12) having iodine excess within the 6 months before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\nNote 1: Iodine excess may be due to consuming foods, dietary supplements or medications with a high content of iodine.\n\nNote 2: iodine excess is defined in the Schedule 1 - Dictionary.\n\n(13) being administered an iodine-containing radiographic contrast agent within the 6 months before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(14) taking amiodarone for a continuous period of at least 2 weeks, within the 1 year before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(15) taking a drug from the specified list of drugs within the 6 months before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\nNote: specified list of drugs is defined in the Schedule 1 - Dictionary.\n\n(16) taking minocycline for at least the 6 months before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(17) taking a drug containing at least 10 milligrams of iodine daily for a continuous period of at least 4 weeks, within the 6 months before the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(18) having a thyroid-stimulating, hormone-secreting pituitary adenoma at the time of the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(19) having a chorionic gonadotrophin-secreting neoplasm at the time of the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\nNote: chorionic gonadotrophin-secreting neoplasm is defined in the Schedule 1 - Dictionary.\n\n(20) having a primary or metastatic neoplasm involving the thyroid gland at the time of the clinical worsening of hyperthyroidism or thyrotoxicosis;\n\n(21) for thyrotoxic crisis only, having an acute precipitating event within the 48 hours before that clinical worsening of hyperthyroidism or thyrotoxicosis;\n\nNote: acute precipitating event and thyrotoxic crisis are defined in the Schedule 1 - Dictionary.\n\n(22) for thyrotoxicosis only:\n\n(a) having struma ovarii at the time of the clinical worsening of thyrotoxicosis;\n\nNote: struma ovarii is defined in the Schedule 1 - Dictionary.\n\n(b) having metastatic thyroid carcinoma containing functional thyroid tissue at the time of the clinical worsening of thyrotoxicosis;\n\n(c) having a form of thyroiditis from the specified list of forms of thyroiditis at the time of the clinical worsening of thyrotoxicosis;\n\nNote: specified list of forms of thyroiditis is defined in the Schedule 1 - Dictionary.\n\n(d) having trauma involving the thyroid gland within the 14 days before the clinical worsening of thyrotoxicosis;\n\nNote: trauma involving the thyroid gland is defined in the Schedule 1 - Dictionary.\n\n(e) ingesting excess thyroid hormone in medication, dietary supplements or in food containing thyroid extracts within the 3 months before the clinical worsening of thyrotoxicosis;\n\n(23) inability to obtain appropriate clinical management for hyperthyroidism or thyrotoxicosis.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(12) to 9(23) apply only to material contribution to, or aggravation of, hyperthyroidism or thyrotoxicosis where the person's hyperthyroidism or thyrotoxicosis was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n acute precipitating event means a physical or psychological stimulus or event that causes a sudden, intense psychological or physical response.\n\nNote: Examples of an acute precipitating event include:\n\n(a) abrupt cessation or lowering of anti-thyroid therapy;\n\n(b) acute illness such as acute myocardial infarction, stroke and congestive heart failure;\n\n(c) acute iodine load;\n\n(d) experiencing an acute, severe, emotional stressor;\n\n(e) infection;\n\n(f) parturition;\n\n(g) physical trauma or injury; and\n\n(h) surgery.\n\n chorionic gonadotrophin-secreting neoplasm means a neoplasm that secretes the beta subunit of human chorionic gonadotrophin, and includes seminoma, choriocarcinoma, non-seminomatous germ cell tumour, hydatidiform mole, teratoma and islet cell tumour.\n\n hyperthyroidism—see subsection 7(2).\n\n iodine excess means:\n\n(a) an average intake of more than 1,100 micrograms of iodine per day for adults, or more than 900 micrograms per day for those aged 18 years and under, for a continuous period of at least 3 months; or\n\n(b) having a urinary iodine concentration of greater than 300 micrograms per litre, or greater than 500 micrograms per litre for pregnant women.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n relevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified list of drugs means:\n\n(a) immune checkpoint inhibitors;\n\n(b) interferon alpha;\n\n(c) interleukin-2;\n\n(d) lenalidomide;\n\n(e) lithium carbonate; or\n\n(f) tyrosine kinase inhibitors.\n\n specified list of forms of thyroiditis means:\n\n(a) acute radiation thyroiditis;\n\n(b) drug-induced thyroiditis;\n\n(c) infectious thyroiditis;\n\n(d) silent thyroiditis; or\n\n(e) subacute thyroiditis.\n\nNote 1: Infectious thyroiditis may be due to a bacterial or fungal infection of the thyroid gland. Organisms that can cause infectious thyroiditis include:\n\n(a) Salmonella species;\n\n(b) bacteria belonging to the Mycobacterium tuberculosis complex; and\n\n(c) Pneumocystis jirovecii and fungi belonging to the species Aspergillus, Candida or Coccidioides.\n\nNote 2: Subacute thyroiditis is also known as de Quervain thyroiditis, granulomatous thyroiditis, giant cell thyroiditis or non-suppurative thyroiditis.\n\n struma ovarii means an ovarian neoplasm defined by the presence of thyroid tissue comprising more than half of the overall mass, that usually occurs as part of a teratoma, but may also occur with a serous or mucinous cystadenoma.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n thyrotoxic crisis means a constellation of severe and life-threatening symptoms of rapid onset in a patient with biochemical evidence of elevated thyroid hormones. Characteristic symptoms and signs are fever, marked tachycardia, heart failure, tremor, nausea and vomiting, diarrhoea, dehydration, restlessness, extreme agitation, delirium and coma.\n\nNote 1: Thyrotoxic crisis is also known as thyroid storm.\n\nNote 2: Thyrotoxic crisis may be the first presentation of undiagnosed hyperthyroidism or thyrotoxicosis, or may complicate existing hyperthyroidism or thyrotoxicosis.\n\n thyrotoxicosis—see subsection 7(3).\n\n trauma involving the thyroid gland means:\n\n(a) a blunt injury or burn injury resulting in soft tissue damage adjacent to or overlying the thyroid gland; or\n\n(b) a penetrating injury, including surgery, to the region of the thyroid gland; or\n\n(c) direct trauma to the thyroid gland.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":5,"scope_assessment":{"changed":true,"description":"This instrument replaces the earlier Statement of Principles (section 4) and, on its face, broadens and clarifies the bases on which a reasonable hypothesis can be raised. Concrete changes visible in this text include: (a) explicit inclusion of several modern drug classes (immune checkpoint inhibitors, tyrosine kinase inhibitors, lenalidomide) in the 'specified list of drugs' (Dictionary), which were less likely to appear in older instruments; (b) addition of an inability-to-obtain-appropriate-clinical-management factor (9(23)), which creates a non-exposure pathway to linkage; (c) clearer numeric thresholds and exposure-duration rules for iodine excess and iodine-containing drugs or preparations (Schedule 1); and (d) explicit separation of factors relevant to 'onset' and to 'clinical worsening' with differing rules about when those worsening factors may be used (section 10(2)). Together these adjustments expand and refine the triggers for entitlement assessments compared with a generic earlier formulation and therefore change the operational scope of eligibility and adjudication."},"complexity_factors":["A moderately sized list of 23 distinct factors/subfactors in section 9, many of which are duplicated for both 'onset' and 'clinical worsening' (leading to repetition and branching logic).","Multiple time windows with different lengths and purposes (48 hours, 2 weeks, 4 weeks, 6 months, 1 year, 3 months) across different factors (section 9).","Several medical exclusions and cross-references (Graves disease, toxic multinodular goitre) which require checking other Statements of Principles (section 7 notes, section 11).","Defined numeric thresholds and laboratory cut-offs (iodine excess: >1,100 µg/day adults or urinary iodine >300 µg/L, different for pregnancy) in the Dictionary (Schedule 1).","Specified lists contained in the Dictionary (drugs and forms of thyroiditis) that require looking up additional items rather than being inline in section 9.","Conditional application of factors for 'material contribution' or 'aggravation' only where the condition pre-existed the service (section 10(2)), adding a causation-layer to the assessment.","Requirement that any factor relied upon must be related to 'relevant service' (section 10(1)), which introduces fact-specific linkage evaluation.","Cross-instrument linkage (repeal of previous SOP and interaction with other SOPs and Acts: VEA and MRCA), so administrators must consider multiple instruments together (sections 4, 5, 11)."],"plain_english_summary":"**What this instrument is and who it affects**\n\n- This is a Statement of Principles issued by the Repatriation Medical Authority (RMA) for deciding whether hyperthyroidism or thyrotoxicosis (and death from those conditions) can be linked to a person's military or peacekeeping service for the purposes of veterans' compensation law (Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004) (see sections 3, 5 and 8).\n\n**What the instrument does, mechanically**\n\n- It replaces the earlier Statement of Principles about these conditions (section 4).\n\n- It defines precisely what is meant by \"hyperthyroidism\" and \"thyrotoxicosis\" and lists specific conditions that are excluded from those definitions (for example, Graves disease and toxic multinodular goitre) (section 7(2)–(3) and notes).\n\n- It lists the specific factual factors that must exist to raise a \"reasonable hypothesis\" that the condition (or death from the condition) is related to a person's relevant service. At least one of the listed factors must be present (section 9). The factors include:\n - recent iodine excess (specific numeric thresholds are defined in the Dictionary) within 6 months of clinical onset or worsening (9(1), 9(12) and Dictionary);\n - administration of an iodine-containing radiographic contrast agent within 6 months (9(2), 9(13));\n - taking amiodarone for at least 2 continuous weeks within the previous year (9(3), 9(14));\n - taking certain specified drugs (immune checkpoint inhibitors, interferon alpha, interleukin-2, lenalidomide, lithium carbonate, tyrosine kinase inhibitors) within 6 months (9(4), Dictionary);\n - taking minocycline for at least 6 months within the previous 6 months (9(5), 9(16));\n - taking a drug containing ≥10 mg iodine daily for ≥4 continuous weeks within the previous 6 months (9(6), 9(17));\n - specified tumours or functional thyroid tissue present at onset or worsening (thyroid-stimulating pituitary adenoma, chorionic gonadotrophin-secreting neoplasm, primary or metastatic thyroid neoplasm) (9(7)–(9), 9(18)–(20));\n - for thyrotoxic crisis, an acute precipitating event within 48 hours (9(10), 9(21));\n - thyrotoxicosis-specific causes such as struma ovarii, metastatic functional thyroid carcinoma, specified forms of thyroiditis, trauma to the thyroid, or ingesting excess thyroid hormone within defined windows (9(11), 9(22) and Dictionary);\n - inability to obtain appropriate clinical management for the condition (9(23)).\n\n- The factors that relate to \"clinical worsening\" (9(12)–(23)) apply only where the person already suffered or contracted hyperthyroidism or thyrotoxicosis before or during (but not as a result of) their relevant service — and then only to material contribution or aggravation (section 10(2)). All listed factors must be related to the person's relevant service to be used in a claim (section 10(1)).\n\n- If a listed factor refers to another injury or disease that itself has its own Statement of Principles, that other Statement of Principles governs how that factor is applied (section 11).\n\n- The instrument contains a Dictionary that sets out medical definitions and numerical thresholds (for example, \"iodine excess\" is defined as average intakes above 1,100 µg/day for adults over at least three months, or urinary iodine concentrations above specified cut-offs) and defines terms such as \"acute precipitating event\", \"thyrotoxic crisis\", \"struma ovarii\", and the specified lists of drugs and forms of thyroiditis (Schedule 1 – Dictionary).\n\n**Why it matters (claimed purpose and practical effects)**\n\n- The RMA states the Statement is based on medical-scientific evidence that hyperthyroidism/thyrotoxicosis can be related to relevant service (section 8). Practically, this Statement sets the medical facts and time windows that decision-makers use when determining whether a veteran's thyroid condition is connected enough to service to qualify under veterans' compensation law.\n\n- Who decides and who pays: decision-makers in the Department of Veterans' Affairs or claims adjudicators apply these criteria when determining entitlement; financial liability (pension, treatment, etc.) flows from a positive entitlement decision under the VEA or MRCA.\n\n**Costs, incentives and administrative impacts**\n\n- Evidence burden: claimants will need medical records, diagnostic tests and medication histories that show the listed exposures or conditions within the time windows (section 9 and Dictionary). The Statement creates discrete evidentiary thresholds (for example, iodine intake/duration, drug exposure windows) that can simplify or complicate proof depending on record availability.\n\n- Potential expansion of eligible claims: adding modern drug classes (immune checkpoint inhibitors, tyrosine kinase inhibitors, lenalidomide) and the inability-to-access-care factor may broaden the set of cases where a reasonable hypothesis can be raised (section 9 and Dictionary). That can increase administrative workload and potential liabilities for the compensation system.\n\n- Interaction with other Statements of Principles: factors that overlap with other diseases defer to the other Statements of Principles, which requires cross-checking and may lengthen decision processes (section 11).\n\n- Implementation discretion: adjudicators must link a listed factor to \"relevant service\" (section 10(1)). That requires factual and temporal assessment, which leaves some scope for case-by-case judgment.\n\n**Practical behaviours the instrument encourages or requires**\n\n- Veterans and treating clinicians will need to document medication use, diagnostic exposures (contrast), iodine intake, and any trauma/acute events with dates to satisfy the time limits the Statement specifies (section 9 and Dictionary).\n\n- Claims decision-makers will use the Statement's lists and thresholds to determine whether a \"reasonable hypothesis\" exists; if it does, the claim proceeds to later stages of medical causation assessment under the VEA/MRCA framework.\n\n**Key textual anchors**\n\n- Authority and application: sections 3 and 5. \n- Medical basis claim: section 8. \n- Required factors (list and time windows): section 9. \n- Relation to service and material contribution/aggravation limits: section 10. \n- Definitions and numerical thresholds: Schedule 1 – Dictionary.\n\n"},"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This instrument maintains the standard scope of Repatriation Medical Authority Statements of Principles. It replaces a 2013 version (No. 27 of 2013) with updated medical evidence but does not expand beyond the traditional purpose of establishing causal factors for veterans' compensation claims. The structure follows the standard template: definitions, factors for onset, factors for worsening, and relationship to service requirements."},"complexity_factors":["Multiple defined terms (15+ definitions in Schedule 1) including technical medical terms like 'chorionic gonadotrophin-secreting neoplasm' and 'struma ovarii'","Parallel structure with 23 separate factors, many duplicated for 'clinical onset' versus 'clinical worsening' scenarios","Cross-references to other Statements of Principles (Graves disease, goitre) requiring external knowledge","Conditional logic distinguishing between hyperthyroidism and thyrotoxicosis — some factors apply to one but not the other (e.g., factors 11 and 22 for thyrotoxicosis only)","Specific quantitative thresholds (e.g., 'at least 10 milligrams of iodine daily for a continuous period of at least 4 weeks', 'urinary iodine concentration of greater than 300 micrograms per litre')","Temporal requirements varying by factor (48 hours, 14 days, 3 months, 6 months, 1 year)","Nested definitions where defined terms themselves contain defined concepts (e.g., 'acute precipitating event' with 8 sub-examples)","Dual legislative framework application (VEA and MRCA with different service categories)"],"plain_english_summary":"This Statement of Principles sets the medical test used to decide whether veterans, peacekeepers and current/former ADF members can plausibly link service to hyperthyroidism or thyrotoxicosis under the VEA and MRCA. Using the lower \"reasonable hypothesis\" standard, it lists medical factors that, if present and connected to service, allow a claim to succeed. It guides the Department of Veterans’ Affairs in recognising service-related thyroid conditions and awarding benefits."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-","history":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-/history","analysis":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-/analysis","conflicts":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-/important-cases","documents":"/api/acts/statement-of-principles-concerning-hyperthyroidism-and-thyrotoxicosis-reasonable-hypothesis-no-5-of-/documents"}}